Search

The European (EU)-based industry for non-leisure games (so called Applied Games, AGs) is an emerging business. As such it is still fragmented and needs to achieve critical mass to compete globally. Nevertheless, its growth potential is widely recognized and even suggested to exceed the growth potential of the leisure games market. The European project Realizing an Applied Gaming Ecosystem (RAGE) is aiming at supporting this challenge. RAGE will help to seize these opportunities by making available an interoperable set of advanced Applied Game (AG) technology assets, as well as proven practices of using such AG assets in various real-world contexts. As described in [1], RAGE will finally provide a centralized access to a wide range of applied gaming software modules, relevant information, knowledge and community services, and related scientific documents, taxonomies, media, and educational resources within an online community portal called the RAGE Ecosystem. Besides this, an integration between the RAGE Ecosystem and relevant social network interaction spaces that arranges and facilitates collaboration that underlie Research and Development (R&D), as well as marketoriented innovation and exploitation will be created in order to support community building, as well as collaborative asset exploitation of User Generated Contents (UGCs) of the RAGE Ecosystem. In this paper, we will describe the integration of the Scientific Publication Platform (SPP) Mendeley [2] into the RAGE Ecosystem. This will allow for automating repetitive tasks, reducing errors, and speeding up time consuming tasks. On the other hand it will support information, UGC, and knowledge sharing, as well as persistency of social interaction threads within Social Networking Sites (SNSs) and Groupware Systems (GWSs) that are connected to the RAGE Ecosystem. The paper reviews relevant use cases and scenarios, as well as related authentication, access, and information integration challenges. In this way, on the one hand a qualitative evaluation regarding an optimal technical integration is facilitated while on the other hand design approaches for supporting features of resulting user interfaces are initiated. [ABSTRACT FROM AUTHOR]

Purpose: Combined-modality treatment (CMT) with 2× ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine) and small-field radiotherapy is standard of care for patients with early-stage favorable Hodgkin lymphoma (HL). However, the role of radiotherapy has been challenged. Positron emission tomography (PET) after 2× ABVD (PET-2) might help to predict individual outcomes and guide treatment., Methods: Between November 2009 and December 2015, we recruited patients age 18 to 75 years with newly diagnosed, early-stage favorable HL for this international randomized phase III trial. Patients were assigned to standard CMT of 2× ABVD and 20-Gy involved-field radiotherapy or PET-guided treatment, omitting involved-field radiotherapy after negative PET-2 (Deauville score < 3). Primary objectives were to exclude inferiority of 10% or more in 5-year progression-free survival (PFS) of ABVD alone compared with CMT in a per-protocol analysis among PET-2-negative patients (noninferiority margin for hazard ratio, 3.01) and to confirm PET-2 positivity (Deauville score ≥ 3) as a risk factor for PFS among CMT-treated patients., Results: We enrolled 1,150 patients. Median follow-up was 45 months. Among 628 PET-2-negative, per-protocol-treated patients, 5-year PFS was 93.4% (95% CI, 90.4% to 96.5%) with CMT and 86.1% (95% CI, 81.4% to 90.9%) with ABVD (difference 7.3% [95% CI, 1.6% to 13.0%]; hazard ratio, 1.78 [95% CI, 1.02 to 3.12]). Five-year overall survival was 98.1% (95% CI, 96.5% to 99.8%) with CMT and 98.4% (95% CI, 96.5% to 100.0%) with ABVD. Among 693 patients who were assigned to CMT, 5-year PFS was 93.2% (95% CI, 90.2% to 96.2%) among PET-2-negative patients and 88.4% (95% CI, 84.2% to 92.6%) in PET-2-positive patients ( P = .047). When using the more common liver cutoff (Deauville score, 4) for PET-2 positivity, the difference was more pronounced (5-year PFS, 93.1% [95% CI, 90.7% to 95.5%] v 80.9% [95% CI, 72.2% to 89.7%]; P = .0011)., Conclusion: In early-stage favorable HL, a positive PET after two cycles ABVD indicates a high risk for treatment failure, particularly when a Deauville score of 4 is used as a cutoff for positivity. In PET-2-negative patients, radiotherapy cannot be omitted from CMT without clinically relevant loss of tumor control.

The European project European and Latin American Systems of Ethics Regulation of Biomedical Research Project (EULABOR) has carried out the first comparative analysis of ethics regulation systems for biomedical research in seven countries in Europe and Latin America, evaluating their roles in the protection of human subjects. We developed a conceptual and methodological framework defining 'ethics regulation system for biomedical research' as a set of actors, institutions, codes and laws involved in overseeing the ethics of biomedical research on humans. This framework allowed us to develop comprehensive national reports by conducting semi-structured interviews to key informants. These reports were summarised and analysed in a comparative analysis. The study showed that the regulatory framework for clinical research in these countries differ in scope. It showed that despite the different political contexts, actors involved and motivations for creating the regulation, in most of the studied countries it was the government who took the lead in setting up the system. The study also showed that Europe and Latin America are similar regarding national bodies and research ethics committees, but the Brazilian system has strong and noteworthy specificities.